JP2022539238A5 - - Google Patents

Info

Publication number
JP2022539238A5
JP2022539238A5 JP2022500019A JP2022500019A JP2022539238A5 JP 2022539238 A5 JP2022539238 A5 JP 2022539238A5 JP 2022500019 A JP2022500019 A JP 2022500019A JP 2022500019 A JP2022500019 A JP 2022500019A JP 2022539238 A5 JP2022539238 A5 JP 2022539238A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
gene therapy
complement
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022500019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539238A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/040741 external-priority patent/WO2021007111A1/en
Publication of JP2022539238A publication Critical patent/JP2022539238A/ja
Publication of JP2022539238A5 publication Critical patent/JP2022539238A5/ja
Pending legal-status Critical Current

Links

JP2022500019A 2019-07-05 2020-07-02 ウイルスベクター療法 Pending JP2022539238A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962871058P 2019-07-05 2019-07-05
US62/871,058 2019-07-05
US201962871700P 2019-07-08 2019-07-08
US62/871,700 2019-07-08
US201962875925P 2019-07-18 2019-07-18
US62/875,925 2019-07-18
US201962935569P 2019-11-14 2019-11-14
US62/935,569 2019-11-14
PCT/US2020/040741 WO2021007111A1 (en) 2019-07-05 2020-07-02 Viral vector therapy

Publications (2)

Publication Number Publication Date
JP2022539238A JP2022539238A (ja) 2022-09-07
JP2022539238A5 true JP2022539238A5 (cg-RX-API-DMAC7.html) 2024-03-25

Family

ID=74114222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500019A Pending JP2022539238A (ja) 2019-07-05 2020-07-02 ウイルスベクター療法

Country Status (6)

Country Link
US (1) US20220249706A1 (cg-RX-API-DMAC7.html)
EP (1) EP3996744A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022539238A (cg-RX-API-DMAC7.html)
AU (1) AU2020311330A1 (cg-RX-API-DMAC7.html)
CA (1) CA3143257A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021007111A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180090785A (ko) 2015-10-07 2018-08-13 아펠리스 파마슈티컬스 인코포레이티드 투여 요법
BR112019020955A2 (pt) * 2017-04-07 2020-05-05 Apellis Pharmaceuticals, Inc. regimes de dosagem e composições e métodos relacionados
JP2021507884A (ja) 2017-12-15 2021-02-25 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. 投与レジメンならびに関連組成物および方法
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
MA71435A (fr) * 2021-05-27 2025-04-30 Apellis Pharmaceuticals, Inc. Édition génomique du complément
US20260043046A1 (en) * 2022-03-17 2026-02-12 Adverum Biotechnologies, Inc. Cassettes of anti-complement component 3 antibody, vectorization and theraputic application
EP4622992A1 (en) * 2022-11-24 2025-10-01 Amyndas Pharmaceuticals US LLC Compstatin analogs for vector-based therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029033A2 (en) * 1998-11-17 2000-05-25 The General Hospital Corporation A method of genetic vector delivery
JP2007112715A (ja) * 2004-01-22 2007-05-10 Dnavec Research Inc 繰返し投与を伴うベクターの発現を継続させる方法
US10035822B2 (en) * 2012-11-15 2018-07-31 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity

Similar Documents

Publication Publication Date Title
JP7707261B2 (ja) 筋疾患の治療のための改変aavカプシドポリペプチド
TWI719223B (zh) 最佳化之微小肌萎縮蛋白基因和表現卡匣及彼等之用途
CA2909733C (en) Effective delivery of large genes by dual aav vectors
ES2989774T3 (es) Factor IX modificado, y composiciones, métodos y utilizaciones para la transferencia génica a células, órganos y tejidos
JP2020048571A5 (cg-RX-API-DMAC7.html)
KR101014207B1 (ko) 아데노-결합 바이러스 (aav) 서열을 검출 및/또는 확인하는 방법 및 그 방법에 의해 확인된 신규한 서열을 분리하는 방법
US10640785B2 (en) Virus vectors for highly efficient transgene delivery
US10392632B2 (en) AAV8 vector with enhanced functional activity and methods of use thereof
AU2003295312B2 (en) Improved rAAV expression systems for genetic modification of specific capsid proteins
US20180036428A1 (en) Capsid-modified raav vectors and methods of use
US20170007720A1 (en) Methods and compositions for gene delivery to on bipolar cells
US20230133924A1 (en) Optimized expression cassettes for gene therapy
JP2015514427A (ja) Aavカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
CN114945583A (zh) Α-肌聚糖的腺相关病毒载体递送和肌营养不良症的治疗
TW201629225A (zh) 第九因子基因療法
CN116685329B (zh) 核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途
AU2023258039A1 (en) B-cell lymphoma 2–associated anthanogene 3 (bag3) gene therapy using aav vector
CN111876432B (zh) 一组肝靶向新型腺相关病毒的获得及其应用
JP2022553083A (ja) アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療
CN118108810A (zh) 一种靶向骨骼肌的重组腺相关病毒及其应用
CA2500523A1 (en) Vp2-modified raav vector compositions and uses therefor
KR20250102134A (ko) Atp7b 유전자 요법
CN117897492A (zh) 用于肌肉和cns中的基因表达的杂合启动子
CN115885043A (zh) 用于dwarf开放阅读框的腺相关病毒载体
EP4410988A1 (en) An aav2-vector variant for targeted transfer of genes